Olokizumab Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Crohn's Disease A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease Phase 2 CD0001 Terminated NCT016356212011-002517-11 LINK Rheumatoid Arthritis Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0056 Completed NCT012424882010-020839-39 Genovese, M. C. et al. Ann Rheum Dis;2014;73;9;1607-1615 Rheumatoid Arthritis Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 Phase 2 RA0057 Completed NCT012967112010-022224-77 Rheumatoid Arthritis Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 RA0083 Completed NCT01463059 Takeuchi, T.et al. Mod Rheumatol;Mod Rheumatol;2016; 26(1):15-23 Rheumatoid Arthritis The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis Phase 2 RA0089 Completed NCT01533714
